Achillion Pharmaceuticals (ACHN) Receives New Coverage from Analysts at B. Riley
B. Riley began coverage on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) in a report published on Thursday morning, Marketbeat reports. The brokerage issued a neutral rating and a $3.50 price objective on the biopharmaceutical company’s stock.
Several other equities analysts have also recently issued reports on ACHN. BidaskClub raised Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, February 5th. Leerink Swann reissued a buy rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Finally, Zacks Investment Research cut Achillion Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. Achillion Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $4.89.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at $2.90 on Thursday. The company has a market capitalization of $399.79, a P/E ratio of -5.92 and a beta of 1.32. Achillion Pharmaceuticals has a 12 month low of $2.58 and a 12 month high of $5.66.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Monashee Investment Management LLC bought a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at approximately $720,000. Opaleye Management Inc. bought a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at approximately $1,267,000. Virtus Fund Advisers LLC bought a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at approximately $349,000. BlackRock Inc. boosted its position in shares of Achillion Pharmaceuticals by 17.7% during the fourth quarter. BlackRock Inc. now owns 11,572,015 shares of the biopharmaceutical company’s stock valued at $33,326,000 after purchasing an additional 1,736,124 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Achillion Pharmaceuticals by 19.1% during the fourth quarter. Swiss National Bank now owns 189,800 shares of the biopharmaceutical company’s stock valued at $547,000 after purchasing an additional 30,400 shares in the last quarter. Institutional investors own 76.78% of the company’s stock.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.